ADX-102 1% Topical Dermal Cream (reproxalap)
ADX-102-SLS-006
Phase 3 small_molecule completed
Quick answer
ADX-102 1% Topical Dermal Cream (reproxalap) for Sjogren-Larsson Syndrome is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Sjogren-Larsson Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed